EP1204672A4 - High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors - Google Patents

High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors

Info

Publication number
EP1204672A4
EP1204672A4 EP00950789A EP00950789A EP1204672A4 EP 1204672 A4 EP1204672 A4 EP 1204672A4 EP 00950789 A EP00950789 A EP 00950789A EP 00950789 A EP00950789 A EP 00950789A EP 1204672 A4 EP1204672 A4 EP 1204672A4
Authority
EP
European Patent Office
Prior art keywords
vegf
inhibitors
nucleic acid
growth factor
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00950789A
Other languages
German (de)
French (fr)
Other versions
EP1204672A1 (en
Inventor
Nebojsa Janjic
Larry Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of EP1204672A1 publication Critical patent/EP1204672A1/en
Publication of EP1204672A4 publication Critical patent/EP1204672A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP00950789A 1999-07-29 2000-07-26 High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors Withdrawn EP1204672A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US364540 1999-07-29
US09/364,540 US6762290B1 (en) 1999-07-29 1999-07-29 High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
PCT/US2000/020478 WO2001009157A1 (en) 1999-07-29 2000-07-26 High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors

Publications (2)

Publication Number Publication Date
EP1204672A1 EP1204672A1 (en) 2002-05-15
EP1204672A4 true EP1204672A4 (en) 2004-06-30

Family

ID=23434941

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00950789A Withdrawn EP1204672A4 (en) 1999-07-29 2000-07-26 High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors

Country Status (5)

Country Link
US (2) US6762290B1 (en)
EP (1) EP1204672A4 (en)
JP (1) JP2003506023A (en)
CA (1) CA2380535A1 (en)
WO (1) WO2001009157A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399022A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
CN102813923B (en) 2003-08-27 2015-04-01 奥普索特克公司 Combination therapy for the treatment of ocular neovascular disorders
EP1918372A4 (en) * 2005-07-05 2009-08-12 Ribomic Inc Nucleic acid capable of binding to immunoglobulin g and use thereof
EP1933850A4 (en) * 2005-09-15 2009-12-23 Univ Duke Aptamers as agonists
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
ES2742284T3 (en) 2012-03-28 2020-02-13 Somalogic Inc Aptamers against PDGF and VEGF and their use in the treatment of conditions mediated by PDGF and VEGF
JP6630273B2 (en) 2013-09-09 2020-01-15 ソマロジック・インコーポレーテッド PDGF and VEGF aptamers with improved stability and their use in the treatment of PDGF and VEGF mediated diseases and disorders
JPWO2016158851A1 (en) * 2015-03-30 2018-01-25 日産化学工業株式会社 Nucleic acid aptamers that bind to vascular endothelial growth factor receptor
US10815486B2 (en) 2017-07-05 2020-10-27 The Research Foundation For The State University Of New York Chemically modified AMPA receptor RNA aptamers
CN113293166B (en) * 2021-05-26 2024-04-19 扬州大学 Nucleic acid aptamer specifically binding KDR and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007364A1 (en) * 1993-09-08 1995-03-16 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands and improved methods for producing the same
WO1996027604A1 (en) * 1995-03-06 1996-09-12 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5459015A (en) 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5811533A (en) 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
BR9207175A (en) 1992-10-28 1995-12-12 Genentech Inc Composition containing vascular endothelial cell growth factor antagonist polypeptide monoclonal antibody amino acid sequence and method of treatment of tumor in mammal
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5859228A (en) 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
RU2177950C2 (en) 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Nucleic acid complexes as ligands of vesical endothelial growth factor (vegf)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
WO1995007364A1 (en) * 1993-09-08 1995-03-16 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands and improved methods for producing the same
WO1996027604A1 (en) * 1995-03-06 1996-09-12 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)

Also Published As

Publication number Publication date
US20040224915A1 (en) 2004-11-11
US6762290B1 (en) 2004-07-13
WO2001009157A1 (en) 2001-02-08
JP2003506023A (en) 2003-02-18
CA2380535A1 (en) 2001-02-08
EP1204672A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
EP1203004A4 (en) HIGH AFFINITY TGF$g(g) NUCLEIC ACID LIGANDS AND INHIBITORS
EP1204672A4 (en) High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors
IL149034A0 (en) Quinazoline derivatives as vegf inhibitors
EP1194074A4 (en) System and method for establishing vascular access
SG117417A1 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
AU2001228742A1 (en) Ligand for vascular endothelial growth factor receptor
EP1233785A4 (en) "bonzo" chemokine receptor antibodies and ligands
AU7511800A (en) Novel target for antiparasitic agents and inhibitors thereof
EP1165586A4 (en) TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS
AU5023300A (en) Vascular endothelial growth factor variants
EP1359972A4 (en) Ocular iontophoretic device and method for inhibiting vascular endothelial growth factor (vegf) using the same
HUP0200827A2 (en) Vascular endothelial cell growth factor variants and uses thereof
DE60009888D1 (en) SUBSTITUTED 3-CYANO- [1.7], [1.5] AND [1.8] NAPHTHYRIDINE INHIBITORS OF TYROSIN KINASEN
HUP0203957A3 (en) Angiogenesis and vascular permeability modulators and inhibitors
IL134463A0 (en) Fast location of address blocks on gray-scale
AU2576501A (en) Protein kinase inhibitors
AU2001259195A1 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
EP1186615A4 (en) Novel protein and dna thereof
GB9924522D0 (en) Enzyme inhibitors
EP1239039A4 (en) Novel polypeptide and dna thereof
AU2600100A (en) Methods and compositions for delivering nucleic acids
EP1174437A4 (en) Melanocyte-stimulating hormone inhibitors
AU2459400A (en) Peptides inhibiting vascular endothelial cell migration
GB9925491D0 (en) Genetic biosensors using chemiluminescence
IL132731A0 (en) Biological deposit system and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020228;LT PAYMENT 20020228;LV PAYMENT 20020228;MK PAYMENT 20020228;RO PAYMENT 20020228;SI PAYMENT 20020228

A4 Supplementary search report drawn up and despatched

Effective date: 20040512

17Q First examination report despatched

Effective date: 20050103

17Q First examination report despatched

Effective date: 20050103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091215